(Q37563372)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19634777%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

review article

1 reference

title

Effect of hormone replacement therapy on inflammatory biomarkers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19634777%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

0 references

0 references

Hormone Replacement Therapy

1 reference

Panagiota Georgiadou

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19634777%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Effihia Sbarouni

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19634777%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19634777%20AND%20SRC:MED&resulttype=core&format=json

Advances in Clinical Chemistry

3 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19634777%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19634777%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

59-93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19634777%20AND%20SRC:MED&resulttype=core&format=json

Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement

3 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Sex differences in health status after coronary artery bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Risk factors that attenuate the female coronary disease advantage

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Hormone replacement therapy and inflammation: interactions in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Inflammatory bio-markers and cardiovascular risk prediction

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Inflammation in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Novel clinical markers of vascular wall inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

VCAM-1 is critical in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Inhibition of intimal hyperplasia after balloon injury by antibodies to intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The combined role of P- and E-selectins in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Intimal hyperplasia after balloon injury is attenuated by blocking selectins

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Adhesion molecule P-selectin and vascular cell adhesion molecule-1 in enhanced heart allograft arteriosclerosis in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Chemokines--chemotactic cytokines that mediate inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Interleukin-1 beta in coronary arteries of patients with ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

CD40 signaling in vascular cells: a key role in atherosclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

C-reactive protein: linking inflammation to cardiovascular complications

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

New Markers of Inflammation and Endothelial Cell Activation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Widespread coronary inflammation in unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Paraoxonase and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Molecular and cellular basis of cardiovascular gender differences

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The protective effects of estrogen on the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Selective agonists of estrogen receptor isoforms: new perspectives for cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

ERbeta has nongenomic action in caveolae

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Estradiol inhibition of arterial neointimal hyperplasia after balloon injury

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Estrogen inhibits the response-to-injury in a mouse carotid artery model

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The effect of hormone replacement therapy and simvastatin on plasma homocysteine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The role of hormone replacement therapy in the prevention of postmenopausal heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

SERMs: current status and future trends

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Activation of transcription by estrogen receptor alpha and beta is cell type- and promoter-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The effects of raloxifene and simvastatin on plasma lipids and endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Raloxifene and estrogen inhibit neointimal thickening after balloon injury in the carotid artery of male and ovariectomized female rats

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Raloxifene inhibits cholesterol aortic content but not atherosclerotic plaque size in oophorectomised cholesterol-fed rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Tamoxifen for the prevention of myocardial infarction in humans: preclinical and early clinical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The nature and utility of the phytoestrogens: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Phyto-oestrogens and Western diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effect of genistein as a selective estrogen receptor beta agonist on the expression of Calbindin-D9k in the uterus of immature rats

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Phytoestrogens and vascular therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of soy isoflavones on atherosclerosis: potential mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Soy isoflavones--phytoestrogens and what else?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Meta-Analysis of the Effects of Soy Protein Intake on Serum Lipids

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Isoflavone aglycone-rich extract without soy protein attenuates atherosclerosis development in cholesterol-fed rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Plant-derived estrogens relax coronary arteries in vitro by a calcium antagonistic mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity--a controlled crossover trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Prospective study on usual dietary phytoestrogen intake and cardiovascular disease risk in Western women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The effect of the phytoestrogen genistein on myocardial protection and preconditioning in hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The effect of the phytoestrogen genistein on myocardial protection, preconditioning and oxidative stress.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Dietary phytoestrogens to prevent cardiovascular disease: early promise unfulfilled

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Unfolding the action of progesterone receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Sex hormones as potential modulators of vascular function in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Vascular Effects of Progesterone : Role of Cellular Calcium Regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

One year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone in women with mild to moderate hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Metabolic and vascular effect of progestins in post-menopausal women. Implications for cardioprotection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of a New Hormone Therapy, Drospirenone and 17-β-Estradiol, in Postmenopausal Women With Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Combination therapy of low-dose medroxyprogesterone acetate and oral estrogen does not affect endothelial function in the forearms of postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

C-reactive protein reassessed

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Increased plasma concentrations of TGF-beta1 after hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effect of simvastatin on serum C-reactive protein during hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Evidence of a Lack of Effect of a Phytoestrogen Regimen on the Levels of C-Reactive Protein, E-Selectin, and Nitrate in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol production

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

HDL and the inflammatory response induced by LDL-derived oxidized phospholipids

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of high- and low-isoflavone (phytoestrogen) soy foods on inflammatory biomarkers and proinflammatory cytokines in middle-aged men and women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Circulating cell adhesion molecules and death in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Controversies regarding hormone therapy: Insights from inflammation and hemostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Does genotype and equol-production status affect response to isoflavones? Data from a pan-European study on the effects of isoflavones on cardiovascular risk markers in post-menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Soluble P-selectin and the risk of future cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of hormone replacement therapy on plaque stability, inflammation, and fibrinolysis in hypertensive or overweight postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effects of oral soy protein on markers of inflammation in postmenopausal women with mild hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Adipose tissue, insulin resistance and low-grade inflammation: implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Monocyte chemoattractant protein-1 but not tumor necrosis factor-alpha is correlated with monocyte infiltration in mouse lipid lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Estradiol suppresses MCP-1 expression In vivo : implications for atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2809%2947003-3

7 January 2021

10.1016/S0065-2423(09)47003-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19634777%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference